Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Accumulated Expenses: 2015-2025

Historic Other Accumulated Expenses for Intellia Therapeutics (NTLA) over the last 7 years, with Sep 2025 value amounting to $15.7 million.

  • Intellia Therapeutics' Other Accumulated Expenses fell 35.40% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year decrease of 35.40%. This contributed to the annual value of $26.4 million for FY2024, which is 3.83% down from last year.
  • Per Intellia Therapeutics' latest filing, its Other Accumulated Expenses stood at $15.7 million for Q3 2025, which was down 31.47% from $22.9 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Other Accumulated Expenses high stood at $32.7 million for Q4 2022, and its period low was $7.9 million during Q3 2021.
  • For the 3-year period, Intellia Therapeutics' Other Accumulated Expenses averaged around $23.7 million, with its median value being $24.3 million (2024).
  • As far as peak fluctuations go, Intellia Therapeutics' Other Accumulated Expenses spiked by 285.44% in 2022, and later slumped by 35.40% in 2025.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Other Accumulated Expenses stood at $17.0 million in 2021, then skyrocketed by 92.50% to $32.7 million in 2022, then fell by 16.13% to $27.4 million in 2023, then dropped by 3.83% to $26.4 million in 2024, then crashed by 35.40% to $15.7 million in 2025.
  • Its Other Accumulated Expenses stands at $15.7 million for Q3 2025, versus $22.9 million for Q2 2025 and $24.7 million for Q1 2025.